Lung Cancer Awareness Month 2026 Highlights Advances in Detection and Treatment

Every November, Lung Cancer Awareness Month raises awareness of one of the world’s leading causes of cancer-related mortality.

Lung Cancer Awareness Month 2026 highlights the global burden of lung cancer and explores how screening, molecular testing and emerging treatments are improving opportunities for earlier diagnosis and personalized care.

According to the International Agency for Research on Cancer (IARC), lung cancer accounted for approximately 2.6 million new cases and 1.9 million deaths globally in 2024, making it the most frequently diagnosed cancer and leading cause of cancer death worldwide.

Lung Cancer Awareness Month 2026 also emphasizes the importance of recognizing risk factors, expanding access to screening and supporting research that could improve patient outcomes.

Xtalks Insights

Get industry leading pharma and biotech news, events and expert insights delivered to your inbox.

First Name *

Email *

By clicking this checkbox, I agree to receive Xtalks communications and understand that I may unsubscribe at any time. Please review the Xtalks privacy policy here.

Protected by reCAPTCHA.

Continue

What topics would you like to hear more about?

Select all that apply.

Science and Discovery Clinical Development Regulatory Safety and Quality Manufacturing and Supply Chain Commercial and Market Access Data AI and Digital Therapeutic Areas

Progress

1 2 3

Next Step

Want to get even more specific?

Help us narrow down the sub-topics that you're most interested in.

Progress

1 2 3

Save Preferences

Thank you!

For webinars, videos, podcasts and more from Xtalks, join our community today.

BECOME A FREE MEMBER

Progress

1 2 3

What Are the Main Risk Factors and Symptoms of Lung Cancer?

Tobacco smoking remains the leading risk factor for lung cancer. However, the disease can also affect people who have never smoked.

Other risk factors include secondhand smoke, radon exposure, air pollution, occupational carcinogens and genetic susceptibility.

According to the World Health Organization (WHO), common symptoms include persistent coughing, chest pain, shortness of breath, unexplained weight loss and coughing up blood.

Because symptoms may initially be mild or mistaken for other respiratory conditions, lung cancer is frequently diagnosed at advanced stages.

How Does Lung Cancer Screening Improve Early Detection?

Early detection can significantly improve treatment opportunities and outcomes.

Low-dose computed tomography (LDCT) screening can identify lung cancer before symptoms develop in individuals at high risk.

In Canada, Ontario’s Lung Screening Program provides risk-based screening for eligible individuals with a significant smoking history.

However, screening participation is still a challenge, and access varies across healthcare systems.

Researchers are also investigating blood-based biomarkers, liquid biopsies and AI-assisted imaging to improve early detection and diagnostic accuracy.

Freenome, a biotechnology company developing blood-based cancer screening tests, received FDA Breakthrough Device designation for its SimpleScreen Lung test in August 2026. The AI-powered test is designed to detect signs of lung cancer in high-risk adults who are not undergoing recommended screening, with positive results prompting follow-up LDCT imaging.

How Are Targeted Therapies and Immunotherapy Advancing Lung Cancer Treatment?

Treatment options have expanded considerably, particularly for non-small cell lung cancer (NSCLC), which accounts for approximately 85% of lung cancer cases.

Molecular testing can identify actionable alterations in genes such as EGFR, ALK, ROS1 and KRAS, helping clinicians select targeted therapies.

In September 2026, the FDA expanded its accelerated approval sevabertinib (Hyrnuo) for first-line treatment of certain patients with advanced HER2-mutated NSCLC. In the SOHO-01 trial, tumors shrank in 75% of 69 patients who had not received previous systemic treatment. Among those who responded, 73% maintained their response for at least six months.

Immunotherapies targeting immune checkpoints, including PD-1 and PD-L1, have also improved treatment options for selected patients.

Five-year results from the Phase III KEYNOTE-671 trial showed improved survival when pembrolizumab (Keytruda) was added to chemotherapy and surgery for patients with resectable NSCLC. Five-year overall survival was 64.6% with the pembrolizumab regimen, compared with 53.6% in the comparison group.

According to the WHO, treatment selection increasingly depends on cancer stage, molecular characteristics and individual patient factors.

Emerging approaches, including antibody-drug conjugates and combination therapies, are being investigated to address treatment resistance and improve long-term outcomes.

Early this month, AbbVie’s investigational ADC telisotuzumab adizutecan (Temab-A) received FDA Breakthrough Therapy designation for certain patients with previously treated, advanced NSCLC. The treatment targets the c-Met protein and is under clinical investigation.

Lung Cancer Awareness Month 2026 Calls for Greater Access to Care

Despite advances in lung cancer research, disparities in screening, diagnosis and treatment continue to affect patient outcomes.

Organizations such as Lung Cancer Canada emphasize the importance of reducing stigma, supporting patients and improving access to care.

Lung Cancer Awareness Month 2026 provides an opportunity to recognize scientific progress while highlighting the need for continued investment in prevention, screening and innovative therapies.

Expanding access to early detection, molecular testing and personalized treatment will remain essential to reducing the global burden of lung cancer.